David Hojnacki
Overview
Explore the profile of David Hojnacki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
919
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reeves J, Bartnik A, Mohebbi M, Ramanathan M, Bergsland N, Jakimovski D, et al.
Ann Clin Transl Neurol
. 2024 Nov;
12(2):267-279.
PMID: 39556505
Objective: Baseline paramagnetic rim lesion (PRL) load predicts disease progression in people with multiple sclerosis (pwMS). Understanding how PRLs relate to other known MS-related factors, and the practical utility of...
2.
Jakimovski D, Kavak K, Patrick K, Mirmosayyeb O, Eckert S, Hojnacki D, et al.
Medicina (Kaunas)
. 2024 Jul;
60(7).
PMID: 39064588
: Pregnancy in mothers with multiple sclerosis (MS) commonly results in significant changes in disease activity and changes in clinical care, including the discontinuation of disease modifying therapy (DMT). This...
3.
Zivadinov R, Jakimovski D, Burnham A, Kuhle J, Weinstock Z, Wicks T, et al.
J Neurol
. 2024 May;
271(8):4949-4962.
PMID: 38758279
Background: A subgroup of people with multiple sclerosis (pwMS) will develop severe disability. The pathophysiology underlying severe MS is unknown. The comprehensive assessment of severely affected MS (CASA-MS) was a...
4.
Jakimovski D, Weinstock-Guttman B, Burnham A, Weinstock Z, Wicks T, Ramanathan M, et al.
Mult Scler Relat Disord
. 2024 Apr;
87:105630.
PMID: 38678969
Background: Expanded Disability Status Scale (EDSS) is limited when utilized in highly disabled people with multiple sclerosis (pwMS). Objetive: To explore the relationship between disability measures and MRI outcomes in...
5.
Jakimovski D, Eckert S, Mirmosayyeb O, Thapa S, Pennington P, Hojnacki D, et al.
Vaccines (Basel)
. 2023 Feb;
11(2).
PMID: 36851227
Background: Persons with neuroinflammatory diseases (pwNID) treated with potent immunosuppressives are at risk of severe COVID-19 outcomes and reduced vaccine seroconversion. We aimed at determining the real-world efficacy of tixagevimab...
6.
Pennington P, Weinstock-Guttman B, Kolb C, Jakimovski D, Sacca K, Benedict R, et al.
J Neurol
. 2022 Dec;
270(2):1120-1126.
PMID: 36574066
No abstract available.
7.
Pennington P, Weinstock-Guttman B, Kolb C, Jakimovski D, Sacca K, Benedict R, et al.
J Neurol
. 2022 Nov;
270(2):1095-1119.
PMID: 36376729
Central nervous system (CNS) atrophy provides valuable additional evidence of an ongoing neurodegeneration independent of lesion accrual in persons with multiple sclerosis (PwMS). However, there are limitations for interpretation of...
8.
Jakimovski D, Zakalik K, Awan S, Kavak K, Pennington P, Hojnacki D, et al.
Vaccines (Basel)
. 2022 May;
10(5).
PMID: 35632451
Background: To determine the effect of disease-modifying therapies (DMT) on humoral postvaccine seroconversion, long-term humoral response, and breakthrough COVID-19 infections in persons with multiple sclerosis (PwMS) and other neuroinflammatory disorders....
9.
Jakimovski D, Zivadinov R, Bergsland N, Ramasamy D, Hagemeier J, Genovese A, et al.
Neuroimage Clin
. 2021 Jan;
29:102554.
PMID: 33472143
Background: Greater brain atrophy is associated with disability progression (DP) in patients with multiple sclerosis (PwMS). However, methodological challenges limit its routine clinical use. Objective: To determine the feasibility of...
10.
Hildesheim F, Ramasamy D, Bergsland N, Jakimovski D, Dwyer M, Hojnacki D, et al.
Mult Scler Relat Disord
. 2020 Dec;
47:102653.
PMID: 33333417
Background: Leptomeningeal contrast enhancement (LMCE) has previously shown potential to be an indirect marker for leptomeningeal inflammation in multiple sclerosis (MS). Dura mater (DME), inclusive falx cerebri (FCE) enhancement and...